Log in Free sign up

Cortexyme (CRTX) News and press releases

News

From Benzinga Pro

Credit Suisse Maintains Underperform on Cortexyme, Lowers Price Target to $3.5

News, Price Target, Analyst Ratings

Credit Suisse analyst Judah Frommer maintains Cortexyme (NASDAQ:CRTX) with a Underperform and lowers the price target from $4 to $3.5.

103 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

77 Stocks Moving In Tuesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves

Biotech, Earnings, M&A, News, Penny Stocks, Guidance, Health Care, Financing, Offerings, Small Cap, FDA, Management, Movers, Trading Ideas, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

Cortexyme Announces Agreement To Acquire Novosteo; Terms Not Disclosed

Expanding pipeline with addition of targeted therapeutics to treat rare skeletal diseases, bone cancer and injury Strengthening leadership team with appointment of Novosteo executives Dr. Dirk Thye as CEO and Dr. Karen

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 1043 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

During Wednesday's trading, 435 companies set new 52-week lows.

Cortexyme Announces Further Layoffs, Chief Medical Officer Leaves

Biotech, News, Penny Stocks, Health Care, General

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs

Biotech, Earnings, News, Penny Stocks, Guidance, Health Care, Financing, Offerings, Small Cap, FDA, Movers, Trading Ideas, General

Here's a roundup of top developments in the biotech space over the last 24 hours.

Stocks That Hit 52-Week Lows On Thursday

News, Options, Intraday Update, Markets

During Thursday, 849 stocks hit new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Monday, 721 companies achieved new lows for the year.

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 431 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Thursday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Thursday, 236 companies hit new 52-week lows.

Cortexyme Provides New GAIN Trial Data At AD/PD 2022 Demonstrating Potential Benefit Of Lysine Gingipain Inhibition In Mild To Moderate Alzheimer's Population

Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, presented new target engagement

Cortexyme Announces Preclinical Data Highlighting Potential Therapeutic Benefits Of Atuzaginstat For The Treatment Of High-Risk Oral Potentially Malignant Disorders

Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today provided an update on both

10 Biggest Price Target Changes For Wednesday

Penny Stocks, Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings

Telsey Advisory Group cut the price target on Stitch Fix, Inc. (NASDAQ: SFIX) from $25 to $14. Stitch Fix shares fell 24.5% to $8.31 in pre-market trading.

HC Wainwright & Co. Maintains Buy on Cortexyme, Lowers Price Target to $15

News, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Andrew Fein maintains Cortexyme (NASDAQ:CRTX) with a Buy and lowers the price target from $30 to $15.

Cortexyme Posts Safety Data From SAD Portion Of COR588 Trial In P.Gingivalis

Biotech, News, Penny Stocks, Health Care, Movers, Trading Ideas, General

Cortexyme Inc (NASDAQ: CRTX) has announced results from the single ascending dose (SAD) portion of the Phase 1 trial of COR588 for diseases related to P. gingivalis infection.

Cortexyme Reports Safety And Pharmacokinetics Results From Single Ascending Dose Portion Of Its Phase 1 Clinical Trial Of COR588; Says OR588 Well-Tolerated In All Dose Cohorts

Biotech, General

COR588 well-tolerated in all dose cohorts Human pharmacokinetics support once daily oral dosing Multiple ascending dose data expected in the second quarter of 2022 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--

Stocks That Hit 52-Week Lows On Wednesday

On Wednesday, 348 companies hit new 52-week lows.

Press releases

From Benzinga Pro

Cortexyme Appoints Dr. Philip Low to Its Board of Directors

Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr.

Cortexyme Successfully Completes Acquisition of Novosteo

Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of its

Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases

Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, announced that the company will

Cortexyme Announces Agreement to Acquire Novosteo

Expanding pipeline with addition of targeted therapeutics to treat rare skeletal diseases, bone cancer and injury Strengthening leadership team with appointment of Novosteo executives Dr. Dirk Thye as CEO and Dr. Karen

Bragar Eagel & Squire, P.C. Is Investigating Agrify, CareDx, Medallion, and Cortexyme and Encourages Investors to Contact the Firm

News, Legal, Press Releases

NEW YORK, May 06, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agrify Corporation (NASDAQ:AGFY), CareDx, Inc.

Bragar Eagel & Squire, P.C. Is Investigating CareDx, Medallion, Cortexyme, and Corcept and Encourages Investors to Contact the Firm

News, Legal, Press Releases

NEW YORK, May 01, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CareDx, Inc. (NASDAQ:CDNA), Medallion Financial

Cortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

News, Legal, Press Releases

BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Cortexyme, Inc. (NASDAQ:CRTX) for potential securities law violations. Investors who have lost money in their Cortexyme, Inc. investment

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Cortexyme (CRTX) for Possible Securities Law Violations, Encourages Investors with Significant Losses to Contact Firm's Attorneys

News, Legal, Press Releases

SAN FRANCISCO, April 26, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Cortexyme, Inc. (NASDAQ:CRTX) investors who suffered significant losses to submit your losses now. The firm is investigating possible securities law

Bragar Eagel & Squire, P.C. Is Investigating Cortexyme, Corcept, RBB, and Verra and Encourages Investors to Contact the Firm

News, Legal, Press Releases

NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cortexyme, Inc. (NASDAQ:CRTX), Corcept

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX

NEW YORK, April 25, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Affirm" or the "Company") (NASDAQ:CRTX). Such investors are advised to contact

Thinking about buying stock in Cortexyme, Borqs Technologies, Sundial Growers, Nokia, or Nordic American Tanker?

Opinion, Press Releases

NEW YORK, April 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRTX, BRQS, SNDL, NOK, and NAT.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cortexyme, Inc. - CRTX

New York, New York--(Newsfile Corp. - April 21, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Affirm" or the "Company") (NASDAQ:CRTX). Such investors are advised to contact

Cortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

News, Legal, Press Releases

BOSTON, April 21, 2022 (GLOBE NEWSWIRE) -- Cortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm BOSTON -- Block

Bragar Eagel & Squire, P.C. Is Investigating Cortexyme, SelectQuote, Corcept, and Core Scientific and Encourages Investors to Contact the Firm

News, Legal, Press Releases

NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cortexyme, Inc. (NASDAQ:CRTX), SelectQuote,

CIR INVESTIGATION: Hagens Berman, National Trial Attorneys, Investigating Cortexyme (CRTX) for Possible Securities Law Violations, Encourages Investors with Significant Losses to Contact Firm

SAN FRANCISCO, April 20, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Cortexyme, Inc. (NASDAQ:CRTX) investors who suffered significant losses to submit your losses now. The firm is investigating possible securities law

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX

News, Legal, Press Releases

NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Affirm" or the "Company") (NASDAQ:CRTX). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX

Legal, Press Releases

NEW YORK, NY / ACCESSWIRE / April 17, 2022 / Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Affirm" or the "Company") (NASDAQ:CRTX). Such investors are advised to

Bragar Eagel & Squire, P.C. Is Investigating CareDx, Medallion, Cortexyme, and SelectQuote and Encourages Investors to Contact the Firm

News, Legal, Press Releases

NEW YORK, April 15, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CareDx, Inc. (NASDAQ:CDNA), Medallion

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX

News, Legal, Press Releases

NEW YORK, April 15, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Affirm" or the "Company") (NASDAQ:CRTX). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX

Legal, Press Releases

NEW YORK, NY / ACCESSWIRE / April 13, 2022 / Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Affirm" or the "Company") (NASDAQ:CRTX). Such investors are advised to